Predictive Oncology Inc. (POAI)
| Market Cap | 75.54M |
| Revenue (ttm) | 1.31M |
| Net Income (ttm) | -28.67M |
| Shares Out | 15.21M |
| EPS (ttm) | -3.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $1.42 |
| Previous Close | $1.54 |
| Change ($) | -0.13 |
| Change (%) | -8.12% |
| Day's Open | 1.38 |
| Day's Range | 1.30 - 1.49 |
| Day's Volume | 2,161,539 |
| 52-Week Range | 0.63 - 4.42 |
POAI ‘s Helomics Division Announces Progress on Milestones for its AI-Driven Model of Ovarian Cancer
Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building Helomics Researchers Complete Key Sequencing Milestones and Focus on AI-Driven Model Building
MINNEAPOLIS, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
MINNEAPOLIS, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and dr...
MINNEAPOLIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
MINNEAPOLIS, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and dr...
MINNEAPOLIS, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
MINNEAPOLIS, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
MINNEAPOLIS, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
MINNEAPOLIS, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
EAGAN, Minn., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and d...
MINNEAPOLIS, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
MINNEAPOLIS, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intel...
Our new PeDAL fee-for-service offering for Pharmaceutical companies will significantly improve the chances of translating discoveries into the clinic Our new PeDAL fee-for-service offering for...
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and dr...
Reincorporation Proposal Received Overwhelming Support Among Shares Voted Reincorporation Proposal Received Overwhelming Support Among Shares Voted
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug ...
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug ...
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology Inc. (NASDA Q : POAI) today announces that its chief executive officer, Carl Schwartz, has been featured ...
EAGAN, Minn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and dr...
Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from Ovarian Cancer Patients. Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from O...
EAGAN, Minn., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine an...
EAGAN, Minn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and...
EAGAN, Minn., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and...
LOS ANGELES, Aug. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to p...
Increases Readiness for Commercialization with Expanded Portfolio of Solutions for Precision Medicine
Annual Meeting of Stockholders to be Held on September 3, 2020 Annual Meeting of Stockholders to be Held on September 3, 2020
Adds Industry, Business Development and Financial Expertise Adds Industry, Business Development and Financial Expertise
Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development
MINNEAPOLIS, June 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (the “Company,” “Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on appl...
A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Pati...
CancerQuest 2020 Study on Schedule for Completion in Q2 2020 CancerQuest 2020 Study on Schedule for Completion in Q2 2020
MINNEAPOLIS, June 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to person...
MINNEAPOLIS, May 14, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of ...
MINNEAPOLIS, May 07, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial inte...
MINNEAPOLIS, May 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensin...
CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Demonstrating Confidence in Company’s Future CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued E...
NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio — Predictive Oncology (NASDAQ: POAI) today announces that Company director and CEO Dr. Carl Schwartz, in an interview with ...
MINNEAPOLIS, March 31, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
MINNEAPOLIS, March 23, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery s...
MINNEAPOLIS, March 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery s...
With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms...
POAI proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-vir...
MINNEAPOLIS, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery se...
New Formulations Will Speed Discovery of Biomarkers and Precision Therapies
AI platform was developed at the Ray and Stephanie Lane Center for Computational Biology, which became the Computational Biology Department at Carnegie Mellon University and was successfully t...
MINNEAPOLIS, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery se...
MINNEAPOLIS, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery se...
About POAI
Predictive Oncology provides various healthcare products and services primarily in the United States. The company operates in three segments: Domestic, International, and Helomics. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' ex... [Read more...]
| Industry Medical Instruments & Supplies | Founded 2002 |
| CEO Carl Schwartz | Employees 29 |
| Stock Exchange NASDAQ | Ticker Symbol POAI |
Financial Performance
In 2019, POAI's revenue was $1.41 million, a decrease of -0.01% compared to the previous year's $1.41 million. Losses were -$19.39 million, 92.2% more than in 2018.